02.08.2021 SYNLAB AG  DE000A2TSL71

DGAP-News: SYNLAB AG: SYNLAB and Medica Sur reach an agreement for SYNLAB to acquire 100 percent of Laboratorio Médico Polanco and Laboratorio Clinicos de Puebla


 

DGAP-News: SYNLAB AG / Key word(s): Takeover/Expansion
SYNLAB AG: SYNLAB and Medica Sur reach an agreement for SYNLAB to acquire 100 percent of Laboratorio Médico Polanco and Laboratorio Clinicos de Puebla

02.08.2021 / 14:20
The issuer is solely responsible for the content of this announcement.


  • SYNLAB will acquire Laboratorio Médico Polanco and Laboratorio Clinicos de Puebla (LMP & LCR), a network of over 100 diagnostic service points in Mexico
  • By integrating LMP & LCR into the international SYNLAB laboratory network, SYNLAB will strengthen its strategic position in the region
  • SYNLAB will be ideally structured and positioned for further expansion and integration of bolt-on acquisitions in Mexico and Latin America

SYNLAB, Europe's leading medical diagnostics services provider, with a presence in five Latin American countries, announces a corporate agreement with Medica Sur to acquire LMP & LCR to increase its presence to Mexico.

With the scheduled acquisition, SYNLAB will incorporate LMP & LCR's dense network of more than 100 diagnostic service points mainly located around Mexico City and Puebla and employing 1,700 people. In 2020, LMP & LCR achieved revenues of MXP 1.3 billion (EUR 55 million), including COVID-19 testing services.

SYNLAB will benefit from LMP's & LCR's excellent reputation gained from their long standing patient-centric approach to diagnostics and commitment to medical excellence. LMP & LCR deliver these high-end diagnostic services directly to patients via their regional network as well as by partnering with local hospitals and third party laboratories. In addition, LMP & LCR provide diagnostic services to corporate clients.

The acquisition of LMP & LCR is an important milestone for SYNLAB's strategy in Latin America. Building up on this newly acquired platform in Mexico and an enthusiastic management team, SYNLAB will bolster cross-border cooperation in the region.

Mathieu Floreani, CEO of SYNLAB, emphasises the strategic surplus of this acquisition for SYNLAB: "The incorporation of LMP & LCR into the SYNLAB network will further strengthen our position in Latin America. It will provide us with a good platform to expand our services in Mexico and beyond. We are also looking forward to welcoming a highly qualified and talented team to the SYNLAB family. With the support of the whole group, the new management team will continue or even accelerate SYNLAB's growth path in the region."

The acquisition is subject to customary anti-trust approvals, with closing expected in Q4 2021. SYNLAB is well on track to exceed, in 2021, the EUR 200 million M&A target set as mid-term guidance.


For more information:

Media contact:
Diana Tabor, FTI Consulting
+49 (0) 151 46693856
[email protected]
Investor contact:
Mark Reinhard, SYNLAB
+49 (0) 170 118 3753
[email protected]
 



About SYNLAB

  • SYNLAB, (ISIN: DE000A2TSL71, SYMBOL: SYAB) is the largest European clinical laboratory and medical diagnostic services company and offers a full range of innovative and reliable medical diagnostics for patients, practising doctors, clinics and the pharmaceutical industry.
  • Providing the leading level of service within the industry, SYNLAB is the partner of choice for diagnostics in human and veterinary medicine. The Group continuously innovates medical diagnostic services for the benefit of patients and customers.
  • SYNLAB operates in 36 countries across four continents and holds leading positions in most markets. More than 20,000 employees, including over 1,200 medical experts, as well as a large number of other specialists such as biologists, chemists and laboratory technicians, contribute every day to the Group's worldwide success. SYNLAB carries out ~500 million laboratory tests per year and achieved revenues of EUR 2.6 billion in 2020.
  • More information can be found on www.synlab.com

 



02.08.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: SYNLAB AG
Moosacher Straße 88
80809 Munich
Germany
Phone: +49 1701183753
E-mail: [email protected]
Internet: www.synlab.com/
ISIN: DE000A2TSL71
WKN: A2TSL7
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1223360

 
End of News DGAP News Service

1223360  02.08.2021 

fncls.ssp?fn=show_t_gif&application_id=1223360&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 0,00 0,00 1.807,90 1.906,10 2.621,20 3.764,92 3.000,00
EBITDA1,2 0,00 0,00 382,90 397,40 679,20 1.179,89 722,00
EBITDA-Marge3 0,00 0,00 21,18 20,85 25,91 31,34 24,07
EBIT1,4 0,00 0,00 138,80 71,90 315,50 914,53 505,00
EBIT-Marge5 0,00 0,00 7,68 3,77 12,04 24,29 16,83
Jahresüberschuss1 0,00 0,00 -42,10 -108,00 259,10 627,54 278,00
Netto-Marge6 0,00 0,00 -2,33 -5,67 9,88 16,67 9,27
Cashflow1,7 0,00 0,00 120,30 238,60 904,70 1.011,70 0,00
Ergebnis je Aktie8 0,00 0,00 -0,19 -0,49 1,16 2,82 1,25
Dividende8 0,00 0,00 0,00 0,00 0,00 0,33 0,35
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Deloitte

INVESTOR-INFORMATIONEN
©boersengefluester.de
Synlab
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2TSL7 17,320 3.848,89
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
12,20 11,11 1,09 17,41
KBV KCV KUV EV/EBITDA
1,71 3,80 1,02 4,14
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,00 0,33 1,91 16.05.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
12.05.2022 11.08.2022 10.11.2022 16.03.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
4,75% -9,56% -26,61% -3,59%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu SYNLAB AG  ISIN: DE000A2TSL71 können Sie bei DGAP abrufen


Medtech , A2TSL7 , SYAB , XETR:SYAB